Pancreatic Cancer Research

ResearcherThe University of OsakaActive in the last 2 years

Yutaka Takeda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7981-2487; OpenAlex author ID A5023602886, A5028305817. Sources: OpenAlex.

Their work

Papers
35 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
71
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 2 papers · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: 8 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 4 papers · 2025: 1 paper · 2026: 2 papers

Papers 35

  1. A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarc… Co-author DOI 10.1007/s00595-026-03481-z↗
  2. Prognostic significance of neoadjuvant gemcitabine and S-1 chemotherapy with or without concurrent radiation in patients with resectable and borderline resecta… Co-author DOI 10.1016/j.surg.2025.109864↗
  3. Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenoca… Co-author DOI 10.1038/s41598-025-23185-7↗
  4. Pancreatic fibrosis assessment and association with pancreatic cancer: comparison with the extracellular volume fraction. Co-author DOI 10.1016/j.crad.2024.08.007↗
  5. Safety and feasibility of minimally invasive distal pancreatectomy for pancreatic cancer in elderly patients: A retrospective study. Co-author DOI 10.1111/ases.13331↗
  6. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline… Co-author DOI 10.1245/s10434-024-15199-8↗
  7. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pa… Co-author DOI 10.1245/s10434-024-15244-6↗
  8. [The Six Cases of Recurrence of Lung Metastasis after Radical Resection of Pancreatic Cancer Performed at Our Hospital]. First author PMID 36927912↗
  9. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
  10. Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.04.029↗
  11. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadj… Co-author DOI 10.1186/s13063-021-05541-w↗
  12. [A Long-Term Survival Case of Locally Advanced Unresectable Pancreatic Adenocarcinoma after Chemoradiotherapy and Conversion Surgery]. First author PMID 35045473↗
  13. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07927-2↗
  14. A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancre… First author DOI 10.1245/s10434-019-07735-8↗
  15. [A Case Report of Conversion Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastasis after Chemotherapy]. First author PMID 31164541↗
  16. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1159/000475477↗
  17. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy. Co-author DOI 10.1245/s10434-018-6431-8↗
  18. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-016-1405-6↗
  19. The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Co-author DOI 10.1007/s00595-017-1522-x↗
  20. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep42339↗
  21. MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Co-author DOI 10.1111/cas.13159↗
  22. Two cases of resectable pancreatic cancer diagnosed by open surgical biopsy after endoscopic ultrasound fine-needle aspiration failed to yield diagnosis: case … Co-author DOI 10.1186/s40792-017-0314-2↗
  23. CT Density in the Pancreas is a Promising Imaging Predictor for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-017-5914-3↗
  24. Patients Treated with Preoperative Chemoradiation for Pancreatic Ductal Adenocarcinoma have Impaired Bone Density, a Predictor of Distant Metastasis. Co-author DOI 10.1245/s10434-017-6040-y↗
  25. [The Treatment Outcomes of FOLFIRINOX for Unresectable and Recurrent Pancreatic Cancer]. First author PMID 29394764↗
  26. [Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience]. Co-author PMID 28133095↗
  27. [Pancreatic Cancer with Liver Metastasis Treated with Radical Surgery after Chemotherapy]. First author PMID 28133194↗
  28. [FOLFIRINOX Combination Chemotherapy in Patients with Metastatic or Recurrent Pancreatic Cancer--A Single Institution Experience]. Co-author PMID 26805364↗
  29. [Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer]. First author PMID 26805366↗
  30. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1093/jjco/hyu143↗
  31. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. Co-author DOI 10.1097/cji.0000000000000020↗
  32. Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer. Co-author DOI 10.5754/hge12974↗
  33. [Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience]. Co-author PMID 24393954↗
  34. Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Co-author DOI 10.1038/onc.2011.59↗
  35. [Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer]. Co-author PMID 21566438↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 23 shared papers, 2011–2026 · strength 2.23
  2. Daisaku Yamada · 16 shared papers, 2017–2026 · strength 1.80
  3. Tadafumi Asaoka · 15 shared papers, 2017–2026 · strength 1.59
  4. Hidetoshi Eguchi · 19 shared papers, 2011–2024 · strength 1.56
  5. Masahiro Tanemura · 18 shared papers, 2011–2025 · strength 1.52
  6. Yoshifumi Iwagami · 12 shared papers, 2017–2026 · strength 1.42
  7. Hirofumi Akita · 9 shared papers, 2011–2026 · strength 1.21
  8. Yoshiteru Katsura · 11 shared papers, 2013–2026 · strength 1.08
  9. Yoshiaki Ohmura · 9 shared papers, 2015–2026 · strength 0.87
  10. Hidenori Takahashi · 6 shared papers, 2011–2026 · strength 0.84
  11. Kunihito Gotoh · 11 shared papers, 2017–2021 · strength 0.78
  12. Osakuni Morimoto · 4 shared papers, 2021–2025 · strength 0.65
  13. Masanori Tsujie · 4 shared papers, 2021–2025 · strength 0.65
  14. Yoshito Tomimaru · 4 shared papers, 2017–2026 · strength 0.57
  15. Hidetoshi Eguchi · 3 shared papers, 2017–2026 · strength 0.55
  16. Kohei Murata · 4 shared papers, 2017–2024 · strength 0.48
  17. Takuya Sakamoto · 5 shared papers, 2016–2023 · strength 0.40
  18. Shinichiro Hasegawa · 2 shared papers, 2017–2026 · strength 0.35
  19. Hidetoshi Eguchi · 1 shared paper, 2026 · strength 0.28
  20. Masaki Mori · 5 shared papers, 2011–2018 · strength 0.25
  21. Yasunari Fukuda · 2 shared papers, 2017–2024 · strength 0.24
  22. Shigeyuki Tamura · 5 shared papers, 2013–2016 · strength 0.22
  23. Hideo Tomihara · 3 shared papers, 2017 · strength 0.19
  24. Noriyuki Tomiyama · 1 shared paper, 2024 · strength 0.18
  25. Hideyuki Fukui · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.